On Monday, Shares of Cognizant Technology Solutions Corporation (NASDAQ:CTSH), gained 6.15% to $62.78, hitting its highest level.
Cognizant Technology Solutions, declared its first quarter 2015 financial results.
Highlights—First Quarter 2015
- First quarter revenue of $2.91 billion was up 20.2% from the year-ago period and up 6.2% sequentially.
- GAAP diluted EPS was $0.62, up from $0.57 in the year-ago period.
- Non-GAAP diluted EPS was $0.71, up from $0.62 in the year-ago period.
- Net headcount addition for the quarter was about 6,200.
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other.
At the end of Monday’s trade, Shares of Constant Contact, Inc. (NASDAQ:CTCT), jumped 6.07% to $29.18.
Constant Contact, declared its financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Financial Metrics
- Revenue was $90.4 million, an enhance of 14.6% contrast to revenue of $78.9 million for the comparable period in 2014.
- Gross margin was 73.0%, contrast to 72.5% for the comparable period in 2014.
- Adjusted EBITDA was $14.7 million, contrast to adjusted EBITDA of $11.0 million for the comparable period in 2014. Adjusted EBITDA margin was 16.2%, contrast to 13.9% for the comparable period in 2014.
- GAAP net income was $3.6 million, or $0.11 per diluted share, contrast to GAAP net income of $850 thousand, or $0.03 per diluted share, for the comparable period in 2014.
- Non-GAAP net income was $7.4 million, contrast to non-GAAP net income of $5.0 million for the comparable period in 2014. Non-GAAP net income per diluted share was $0.22 per share, contrast to $0.16 per share for the comparable period in 2014.
- Cash flow from operations was $20.2 million, contrast to $11.1 million for the comparable period in 2014.
- Capital expenditures were $5.3 million, contrast to $5.9 million for the comparable period in 2014.
- Free cash flow was $15.0 million, contrast to $5.2 million for the comparable period in 2014.
- The company had $179.1 million in cash, cash equivalents and marketable securities at March 31, 2015, contrast to $162.6 million at December 31, 2014.
Constant Contact, Inc. provides online marketing tools that are designed for small organizations worldwide. The company seeks to assist its customers succeed by creating and growing their customer and member relationships through its products combined with education, support, KnowHow, and coaching.
Pacific Biosciences of California, Inc. (NASDAQ:PACB), ended its last trade with 6% gain, and closed at $6.01.
Pacific Biosciences, declared that BGI, the world’s largest genomics organization, has purchased its first PacBio RS II instrument and plans to purchase additional units in order to integrate Single Molecule, Real-Time (SMRT(R)) Sequencing into its global service business.
The PacBio RS II delivers the industry’s longest read lengths combined with unbiased coverage and high accuracy. These characteristics enable customers to access the complete spectrum of sequence variant types, from single nucleotide polymorphisms to complex structural variation, and from genomic regions that were formerly inaccessible. In addition, SMRT Sequencing is the only technology that provides direct detection of base modifications and direct variant phasing information across full-length genes and chromosome haplotype blocks.
Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes.
Finally, Advaxis, Inc. (NASDAQ:ADXS), closed at $18.09, with 5.98% gain.
Advaxis, declared the pricing of its formerly declared underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock from Advaxis. The gross proceeds to Advaxis from the public offering are predictable to be $53.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is predictable to close on May 5, 2015, subject to customary closing conditions. Advaxis intends to use the net proceeds from the public offering to fund its continued research and development initiatives in connection with expanding its product pipeline and for other general corporate purposes.
Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering, Guggenheim Securities, LLC is acting as lead manager, and Janney Montgomery Scott LLC, Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-managers.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
